Loading clinical trials...
Loading clinical trials...
A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib Vs. Placebo in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia Patients with Risk of Early Disease Progression
Conditions
Interventions
Ibrutinib
Placebo
Locations
1
Germany
German CLL Study Group
Cologne, Germany
Start Date
April 30, 2014
Primary Completion Date
March 7, 2019
Completion Date
July 11, 2022
Last Updated
December 30, 2024
NCT07277231
NCT05006716
NCT06859424
NCT05254743
NCT01804686
NCT05371808
Lead Sponsor
German CLL Study Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions